Program Goal and Objectives

The purpose of this law home study activity is to introduce the participant to key issues associated with collaborative pharmacy practice, including provisions and regulations specific to practice in the state of New Jersey. Provisions advocated by the Medical Society of New Jersey regarding the conditions for engaging in collaborative practice, requirements pertaining to the pharmacist-collaborating physician relationship, and additional continuing education specifications will be explored.

At the completion of this program, the participant will be able to: define key terms relating to collaborative practice, discuss how collaborative practice between pharmacists and physicians can impact patient outcomes, describe the History of Board of Pharmacy Regulations regarding Collaborative Practice, identify Board of Pharmacy regulations governing Collaborative Practice, describe potential issues facing pharmacists in the collaborative Practice setting and discuss current compensations challenges for those involved in Collaborative Practice.

Continuing Education Credit

Release Date: 10/07/2015
Expiration Date: 10/07/2016 No credit will be give after the expiration date

Fee: The fee for this educational activity is $20

Program Audience: Registered Pharmacists and Pharmacy Technicians

This program is approved for 0.10 CEUs (1.00 contact hours) law continuing education credits. In order to receive 1.00 law contact hours of CE credits, the participant must read the slides, complete the post-test questions with at least a score of 70% and complete the evaluation form. If participant fails first time, may retake the post-test questions at an additional fee of $20. Continuing education credits (paperless) can be viewed at www.MyCPEmonitor.net two weeks
after passing the post-test questions. The Universal Activity Number is 0038-0000-15-011-H03-P-T

Course Development

Angelo Cifaldi, R.Ph., J.D.
ACifaldi@wilentz.com
Adjunct Associate Professor or Pharmacy Law,
Rutgers University, Ernest Mario School of Pharmacy
Wilentz, Goldman and Spitzer Attorneys at Law

Satish V. Poondi, R.Ph., Esq.
Spoondi@wilentz.com
732-855-6154
Wilentz, Goldman, & Spitzer P.A
90 Woodbridge Center Drive
Woodbridge, NJ 07095

Reviewer

Mary Bridgeman, PharmD, BCPS, CGP
Clinical Assistant Professor
Rutgers University, Ernest Mario School of Pharmacy
Internal Medicine/Nephrology
Robert Wood Johnson University Hospital

Contact Person

Please contact Gerry Murphy, Program Coordinator, should problems related to the content or functioning of the continuing education activity arise:

Email: gemurphy@pharmacy.rutgers.edu
Telephone: 848-445-6823 (8:00 am - 4:00 pm - Monday thru Friday)
Mail: Gerry Murphy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road – Room 102A
Piscataway, NJ 08854
Post-Test Questions
(Circle your answers on the Post-Test Answer Form on page 5)
(Mailing instructions are also on page 5)

“Collaborative Practice: the future of pharmacy practice?”

(Knowledge-Based CPE Activity) UAN #0038-0000-15-011-H03-P-T

1. A bona fide physician-patient relationship is satisfied if:
   A. The physician-patient relationship has existed for at least one year
   B. The physician-patient relationship has existed for at least 6 months
   C. The physician-patient relationship has existed for at least 3 months
   D. The physician-patient relationship has existed for at least 1 month

2. True or False: Studies indicate that patient outcomes improve where pharmacists are working in collaboration with physicians and other healthcare providers.
   A. True
   B. False

3. The New Jersey Collaborative Practice Agreement was jointly promulgated by the New Jersey Board of Pharmacy and:
   A. Board of Dentistry
   B. Board of Family Therapists
   C. Board of Medical Examiners
   D. No other professional boards were involved.

4. True or false: The regulations require informed consent from the patient, whether conveyed verbally or in writing.
   A. True
   B. False

5. If a pharmacist wishes to enter into a collaborative practice agreement, he/she must:
   A. Get prior approval from the Board
   B. Obtain continuing education credit
   C. Adopt collaborative practice protocols
   D. All of the above.
6. A pharmacist engaging in collaborative practice must be cognizant of which type of liability:

   A. Administrative
   B. Civil
   C. Criminal
   D. All of the above

THE END OF QUESTIONS
Pharmacy Program Post-Test Answer Form
(Circle answers and mail this page with Name Form and Evaluation Forms on pgs. 6, 7 & 8)

Pharmacy Law Home Study

“Collaborative Practice: the future of pharmacy practice?”

UAN # 0038-0000-15-011-H03-P-T
(Knowledge-based CPE activity)

This form must be completed to receive law continuing education credit. Circle your answers to the questions at the right. You can either email Post-Test Answer Form and Evaluation Form to: gemurphy@pharmacy.rutgers.edu or fax to: 732-445-5767 with credit card info – fee $20
or
Mail Post-Test Answer Form, Evaluation Form and $20 check made to:

Rutgers, The State University of New Jersey
Continuing Education
Ernest Mario School of Pharmacy
160 Frelinghuysen Road, Room 102A
Piscataway, NJ 08854-8020

The Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program is approved for 0.100 CEUs (1.0 contact hours) law continuing education credits. In order to receive 1 law contact hours of CE credits, the participant must read the slides, complete the post-test questions with at least a score of 70% and complete the evaluation form. If participant fails first time, may retake the post-test questions at an additional fee of $20. Continuing Education credits (paperless) can be viewed at www.MyCPEmonitor.net two weeks after passing the post-test questions. The Universal Activity Number is 0038-0000-15-011-H03-P-T

Initial Release Date: 10/07/2015 Expiration Date: 10/07/2016
Pharmacy Law Home Study

“Collaborative Practice: the future of pharmacy practice?”

UAN # 0038-0000-15-011-H03-P-T
(Knowledge-based CPE activity)

NAME FORM

Name________________________________________________________________________
(Print only)

Check one, if applicable:
R.Ph. _______ Pharm.D. ______  Other (specify)________________________________

YOU MUST Provide: NABP e-Profile #____________ Date of Birth:___________

(to acquire a NABP #....... please go to: http://www.nabp.net)

Home Address_________________________________________________________________
City________________________ State______________ Zip Code____________

Telephone (work)________________________________ (home)________________________________

Email________________________________________________________________________

Credit Card Information

Name of Credit Card:________________________ Credit Card #:________________________

Expiration Date:________________________ 3 or 4 digit code on back of card:______________
PROGRAM EVALUATION
(Circle your rating and mail with Post-Test Answer Form pg. 5)

Pharmacy Law Home Study

“Collaborative Practice: the future of pharmacy practice?”

UAN # 0038-0000-15-011-H03-P-T
(Knowledge-based CPE activity)

Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy would appreciate your comments on the quality of this educational activity. Please rate the following by using a 5-point grading system, with 1 being the lowest rating (strongly disagree/poor) and 5 being the highest rating (strongly agree/excellent).

<table>
<thead>
<tr>
<th>Did this program meet the following learning objectives?</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Define key terms relating to collaborative practice?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>2. Discuss how collaborative practice between pharmacists and physicians can impact patient outcomes?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>3. Describe the History of Board of Pharmacy Regulations regarding Collaborative Practice?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>4. Identify Board of Pharmacy regulations governing collaborative Practice?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>5. Describe potential issues facing pharmacists in the collaborative Practice setting?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>6. Discuss current compensations challenges for those involved in Collaborative Practice?</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

What aspects of this activity were of most interest to you?

_________________________________________________________________
_________________________________________________________________
Do you have any comments or suggestions for this or future activities?

________________________________________________________________________

Thank you for your interest in Rutgers, The State University of New Jersey, Ernest Mario School of Pharmacy